Eli Lilly And Company Reports Positive One-Year Phase 3 SHINE-2 Results Of Omvoh In Pediatric Ulcerative Colitis
Eli Lilly reported positive one-year Phase 3 SHINE-2 study results for Omvoh in pediatric ulcerative colitis, with 50% of responders achieving clinical remission at Week 52. The study met its primary endpoint. Omvoh is approved for adults but not yet for pediatric use. The safety profile was consistent with adult data, with no new safety signals. Lilly is studying mirikizumab in pediatric inflammatory bowel disease.
How this was made
The 30-second read
Why it matters
Positive data could expand the drug's label, increase sales potential, and boost Lilly's pipeline credibility in pediatric IBD.
Market read
First disclosure of pivotal pediatric data for a major biotech drug, likely to move LLY and influence the broader IBD therapeutic space.
What to watch
Small trial size (63 patients) and single‑arm design may limit confidence until larger confirmatory studies
Background
Eli Lilly's Omvoh (mirikizumab) is already approved for adult ulcerative colitis and Crohn's disease. The SHINE-2 study is the first pediatric Phase 3 trial for this indication.
Ticker impact
Eli Lilly reported positive Phase 3 SHINE-2 one‑year results for Omvoh in pediatric ulcerative colitis, a first disclosure of pivotal trial data.
likely upward pressure as market prices in the new indication potential
First report of pivotal data for a high‑profile IL‑23p19 inhibitor; investors typically reward such breakthroughs.
Market effects
strengthens outlook for biotech firms developing IL‑23 inhibitors and pediatric IBD therapies
U.S. biotech sector may see modest gains; European peers with similar pipelines could benefit
global investors watch pediatric IBD pipeline progress; could influence cross‑border biotech funding
Counterpoint
If regulatory hurdles delay approval, the stock may underperform despite positive data
Key entities
- companyEli Lilly and Company
Pharmaceutical company developing Omvoh
- drugOmvoh (mirikizumab)
IL‑23p19 inhibitor under investigation for pediatric ulcerative colitis
